I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)

Haemonetics Corporation (HAE) reported Q1 FY2026 results that exceeded expectations for margins and cash flow, despite a headline revenue decline attributed to strategic portfolio exits and one-time factors. While recent growth has paused due to portfolio shifts and competition, the blood-management franchise is viewed as high-quality with a compelling valuation of approximately 11x forward EPS and 8x EV/EBITDA, suggesting attractive upside potential contingent on improved execution and continued free cash flow generation.

Analysis

Haemonetics Corporation (HAE) presents a case of strong underlying fundamentals masked by near-term strategic adjustments. Despite a headline revenue decline in its Q1 FY2026 results, the company surpassed expectations on margins and cash flow, indicating robust operational control. The revenue contraction is attributed to deliberate portfolio exits and other one-time factors, rather than a deterioration in its core blood-management franchise, which retains significant moats in its TEG and plasma software platforms. The company's valuation appears compelling at approximately 11x forward EPS and 8x EV/EBITDA. This, combined with strong free cash flow generation and the potential for margin expansion, suggests an attractive risk/reward profile, with future upside heavily contingent on management's successful execution and a return to organic growth. Furthermore, the company's established U.S. presence is complemented by underpenetrated international markets, offering a clear path for long-term expansion.

Key Decisions for Investors

• Given the compelling valuation and strong underlying cash flow despite a strategic revenue dip, investors may consider the current price an attractive entry point, viewing the recent pause in growth as temporary.
• Monitor management's execution closely in the upcoming quarters for evidence that the portfolio shifts are complete and that organic, top-line growth is resuming, as this is the key catalyst for unlocking value.
• Investors should assess the company's progress in expanding its high-margin TEG and plasma platforms into international markets, as this represents a significant long-term growth driver beyond the current operational noise.